Myriad Says Invitae Is Infringing Cancer Testing Patents

Law360, New York (November 26, 2013, 4:41 PM EST) -- Myriad Genetics Inc. on Monday accused genetic testing company Invitae Corp. of infringing on patents related to cancer-testing, marking the latest front in a growing legal battle that has ensnared four other companies.

In a complaint filed in Utah federal court, Myriad claims that Invitae is infringing on 11 patents for products that assess consumers’ risk for breast and colon cancer. According to the suit, the action was prompted by a Nov. 19 announcement on Invitae’s website offering genetic testing services for the BRCA1 and BRCA2...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.